Can Nordic companies extend the life of Keytruda?

Merck’s cancer drug Keytruda is one of the best-selling drugs in the world right now. But with the main patent expiring in 2028, the pharmaceutical giant has begun to review its strategy to maintain its top spot on the oncology market. BioStock has taken a closer look at the history of Keytruda, what lies ahead and what that means for biotech companies in the Nordic region.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/12/can-nordic-companies-extend-the-life-of-keytruda/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se